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The prognosis of community-acquired pneumonia ranges from rapid resolution of symptoms and full recovery
of functional status to the development of severe medical complications and death. The pneumonia severity
index is a rigorously studied prediction rule for prognosis that objectively stratifies patients into quintiles of
risk for short-term mortality on the basis of 20 demographic and clinical variables routinely available at
presentation. The pneumonia severity index was derived and validated with data on 150,000 patients with
community-acquired pneumonia by use of well-accepted methodological standards and is the only pneumonia
decision aid that has been empirically shown to safely increase the proportion of patients given treatment in
the outpatient setting. Because of its prognostic accuracy, methodological rigor, and effectiveness and safety
as a decision aid, the pneumonia severity index has become the reference standard for risk stratification of
community-acquired pneumonia.
Understanding the prognosis of community-acquired
pneumonia (CAP) is important from clinical, research,
and quality-improvement perspectives [1]. From a clin-
ical perspective, accurate prognostication allows phy-
sicians to inform patients about the expected outcomes
of an acute illness. Furthermore, the ability to quantify
the probability of serious adverse events (i.e., severe
medical complications or death) can assist physicians
in their initial management decisions, such as deter-
mining the most appropriate site of treatment (home
vs. hospital), the intensity of hospital management
(medical floor vs. intensive care unit), and the intensity
of diagnostic testing and/or antibiotic therapy.
From a research perspective, both clinical trials and
comparative effectiveness studies often compare the
clinical outcomes of 1 group of patients who differ
with respect to the performance of a specified process
of care (e.g., performance of blood cultures or initiation
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of antibiotic therapy within 4 h after presentation) or
antibiotic treatment regimen. In such studies, it is im-
perative to assess whether observed differences in pa-
tient outcomes between treatment groups are con-
founded by inherent differences in illness severity,
determined using well-validated severity measures. Ob-
jective risk stratification is also useful for comparing
illness severity across study populations ascertained
over different time periods and across diverse geo-
graphic areas, to ensure that study findings are com-
parable and generalizable to the types of patients cared
for in a given clinical setting.
From a quality-improvement perspective, prediction
rules for prognosis can be used to calculate severity-
adjusted mortality rates in ongoing health care quality-
assurance programs. Observation of severity-adjusted
mortality rates that are statistically significantly higher
than expected when aggregated at either the physician
or the hospital level may identify deficiencies in quality
of care. In the future, these severity-adjusted mortality
rate estimates may be used to identify performance
outliers and/or as part of pay-for-performance policies
that remunerate providers, hospitals, and health care
systems on the basis of such quality metrics.
Over the past decade, several pneumonia-specific
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Figure 1. Assignment to risk class based on the pneumonia severity index. BUN, blood urea nitrogen; yr, years.
Table 1. Thirty-day mortality rate by pneumonia severity index (PSI) risk
class in the derivation and validation cohorts.
PSI risk class
(no. of points)
30-Day mortality rate, %
P
MedisGroups
derivation cohort
( )np 14,199
MedisGroups
validation cohort
( )np 38,039
PORT validation
cohort
( )np 2287
I 0.4 0.1 0.1 .22
II (70) 0.7 0.6 0.6 .67
III (71–90) 2.8 2.8 0.9 .12
IV (91–130) 8.5 8.2 9.3 .69
V (1130) 31.1 29.2 27.0 .09
All classes 10.2 10.6 5.2 …
NOTE. Adapted from [7]. PORT, Pneumonia Patient Outcomes Research Team.
prediction rules for prognosis have been published that define
severity of illness on the basis of a predicted risk of short-term
mortality [2–11]. We focus on the most rigorously studied
prediction rule, the pneumonia severity index (PSI) [7], which
categorizes patients into 5 risk classes, each with an incremental
likelihood of mortality within 30 days (figure 1). Our goals are
(1) to describe the derivation and validation of the PSI, (2) to
review its primary clinical application, and (3) to compare the
performance of the PSI with that of another commonly used
disease-specific prediction rule for prognosis, on the basis of
empirical studies.
DERIVATION AND VALIDATION OF THE PSI
The PSI was originally developed as part of the Pneumonia
Patient Outcomes Research Team (PORT) project, with the goal
of deriving a clinically applicable prediction rule for short-term
mortality among patients with CAP [7]. The underlying hy-
pothesis was that patients with CAP who are at low risk of
mortality can be identified at presentation by use of readily
available clinical information. The PSI was derived by analyzing
data on 14,199 adult inpatients with a principal diagnosis of
pneumonia based on the criteria of The International Classi-
fication of Diseases, Ninth Revision, Clinical Modification (or a
secondary diagnosis of pneumonia with a primary diagnosis of
sepsis or respiratory failure) in the 1989 MedisGroups Com-
parative Hospital Database. The database contained 1250 de-
mographic characteristics and baseline clinical variables for pa-
tients discharged from 78 hospitals in 23 US states [7]. In the
derivation, we identified 20 prognostic variables that were in-
dependently associated with mortality and that were routinely
available to physicians at the time of patient presentation: 3
demographic characteristics (age, sex, and nursing home res-
idence), 5 coexisting illnesses (active neoplastic disease, con-
gestive heart failure, cerebrovascular disease, renal disease, and
liver disease), 5 findings of physical examination (pulse rate,
respiratory rate, systolic blood pressure, temperature, and men-
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Table 2. Studies that assessed the effectiveness and safety of the pneumonia severity index (PSI) for the initial site of treatment.
Study
characteristic Atlas et al. [14] Marrie et al. [15] Carratala` et al. [16] Yealy et al. [17] Renaud et al. [18]
Design Prospective, quasi-ex-
perimental study with
historical controls
Cluster-randomized ef-
fectiveness trial
Randomized, controlled
efficacy trial
Cluster-randomized effec-
tiveness trial
Prospective, con-
trolled study
Sites 1 Tertiary care ED in the
US
19 EDs in Canada 2 Tertiary care EDs in
Spain
32 EDs in the US 16 EDs in France
Patients 313 Immunocompetent
adults, PSI risk clas-
ses I–III
1072 Immunocompe-
tent adults, PSI risk
classes I–III
224 Immunocompetent
adults, PSI risk clas-
ses II and III
1901 Immunocompetent
adults, PSI risk classes
I–III
449 Immunocompe-
tent adults, PSI risk
classes I–III
Intervention Recommendation to
give patients in PSI
risk classes I–III treat-
ment at home
Recommendation to
give patients in PSI
risk classes I–III
treatment at home
Random allocation to
outpatient or inpatient
treatment
Recommendation to give
patients in PSI risk
classes I–III treatment
at home implemented
with 3 strategies (low,
moderate, and high
intensity)
Recommendation to
give patients in PSI
risk classes I–III
treatment at home
Results Patients who received
outpatient care: inter-
vention group, 57%;
historical control
group, 42%. No dif-
ference in mortality
between groups
Patients who received
outpatient care: in-
tervention group,
69%; control group,
51%. No difference
in mortality be-
tween groups
Nonsignificant differ-
ences in QOL, medi-
cal complications, re-
hospitalization, and
mortality between
outpatients and inpa-
tients; greater overall
satisfaction among
outpatients
Patients who received
outpatient care: low-in-
tensity strategy, 38%;
moderate-intensity
strategy, 61%; high-in-
tensity strategy, 62%.
No difference in mortal-
ity between groups
Patients who re-
ceived outpatient
care: intervention
group, 43%; control
group, 24%. Lower
mortality among in-
tervention group
NOTE. ED, emergency department; QOL, quality of life.
tal status), 6 laboratory measurements (blood urea nitrogen,
glucose, hematocrit, and sodium levels; partial pressure of ar-
terial oxygen; and arterial pH), and 1 radiographic finding
(pleural effusion). The primary outcome was in-hospital mor-
tality within 30 days after admission. The PSI was developed
in 2 steps, to parallel more closely the clinical decision-making
processes of physicians in the office or emergency department
setting. In step 1, the PSI identified a subgroup of patients at
very low risk of death (risk class I) solely on the basis of the
presence or absence of 11 findings of medical history and phys-
ical examination (figure 1). In step 2, the risk of death was
quantified for the remaining, non–risk class I patients by use
of the same findings used in step 1 in addition to the laboratory
and radiographic variables that compose the PSI. A total point
score is calculated by summing the integer-based prognostic
weights of each prognostic variable identified for a given pa-
tient. On the basis of the total point score, patients are classified
into 4 additional risk classes (II–V), each with an increased
probability of mortality (figure 1).
The PSI was then retrospectively validated using a 1991
Pennsylvanian MedisGroups database of 38,039 adults hospi-
talized with CAP in 193 hospitals in Pennsylvania [7]. The PSI
was also validated in 2287 US and Canadian inpatients and
outpatients, aged 18 years, whose cases were managed at 5
medical centers participating in the Pneumonia PORT pro-
spective cohort study [7]. No statistically significant differences
in mortality were found across each of the 5 risk classes among
the initial derivation and 2 validation cohorts (table 1). There
was also a statistically significant relationship between higher
risk class and other adverse medical outcomes in the PORT
cohort. For example, among outpatients, there was a statistically
significant increase in the risk of subsequent hospitalization
with higher risk class; among inpatients, the rates of admission
to the intensive care unit and the length of hospital stay also
increased with higher risk class. Among the 1575 patients in
the 3 lowest risk classes who participated in the PORT cohort
study, there were only 7 deaths (0.4%), 4 of which were pneu-
monia related. Thus, the PSI is a validated prediction rule for
prognosis that accurately identifies patients with CAP who are
at low risk for mortality and other adverse outcomes.
One of the major strengths of the PSI that distinguished it
from previous prognostic models for CAP was that it met the
vast majority of methodological standards for the derivation
and validation of clinical prediction rules [12, 13]. It was de-
rived using well-defined and relevant predictor variables and
an unambiguous set of outcomes. The methods used to con-
struct the rule avoided any biases in the assessment of the
relevant predictor or outcome variables. The original work ad-
equately described the underlying mathematical and/or statis-
tical models and disclosed the rule’s expected error rates. The
generalizability and reproducibility of the rule were supported
by its validation in thousands of patients across hundreds of
clinical sites and diverse geographic areas. Although the PSI
was used to make projections of its effectiveness and safety in
guiding the initial site of treatment for patients with CAP in
the PORT cohort study, the initial derivation and validation of
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Table 3. Methodological standards for development and evaluation of clinical prediction rules.
Level of evidence Definitions and standards of evaluation Implications for clinicians
Level 1: derivation of prediction rule Identification of predictors using multivariate
model; blinded assessment of outcomes
Needs validation and further evaluation be-
fore being used clinically in actual patient
care
Level 2: narrow validation of prediction rule Verification of predictors when tested pro-
spectively in 1 setting; blinded assessment
of outcomes
Needs validation in varied settings; may use
predictions cautiously for patients similar to
sample studied
Level 3: broad validation of prediction rule Verification of predictive model in varied set-
tings with wide spectrum of patients and
physicians
Needs impact analysis; may use predictions
with confidence in their accuracy
Level 4: narrow-impact analysis of prediction
rule used as decision rule
Prospective demonstration in 1 setting that
use of prediction rule improves physicians’
decisions (improving quality or effective-
ness of patient care)
May use cautiously to inform decisions in
settings similar to that studied
Level 5: broad-impact analysis of prediction rule
used as decision rule
Prospective demonstration in varied settings
that use of prediction rule improves physi-
cians’ decisions for a wide spectrum of
patients
May use in varied settings with confidence
that its use will benefit quality or effective-
ness of patient care
NOTE. Adapted from [19], with permission from the American College of Physicians.
the PSI fell short of assessing the effect of this prediction rule
on actual patient care. Such applications awaited further clinical
studies of the safety and effectiveness of the PSI as a decision
aid.
EFFECTIVENESS AND SAFETY OF THE PSI
IN GUIDING CLINICAL PRACTICE
Since the publication of the PSI in 1997, 5 studies have assessed
the impact of the PSI on guiding the decision about the initial
site of treatment for patients with CAP (table 2). In a pro-
spective, quasi-experimental study conducted by Atlas et al.
[14] in a single US hospital emergency department, physicians
were provided with the PSI risk class and the risk class–specific
mortality rates for 166 consecutive low-risk (risk classes, I–III)
patients with CAP, coupled with a recommendation to provide
treatment to these patients in the outpatient setting. Compared
with a historical control group of 147 low-risk patients with
CAP, the percentage of patients who initially received treatment
as outpatients increased statistically significantly, from 42%
during the historical control period to 57% during the inter-
vention period, without an increase in the 30-day mortality
rate. However, during the intervention period, more outpa-
tients were subsequently admitted to the study hospital, com-
pared with during the historical control period (9% vs. 0%).
In a large, cluster-randomized effectiveness trial that enrolled
1072 low-risk patients with CAP from 19 Canadian hospital
emergency departments, the implementation of a critical path-
way recommending outpatient care for patients in PSI risk
classes I–III statistically significantly increased the proportion
of low-risk patients treated in the outpatient setting, from 51%
at control sites to 69% at intervention sites [15]. Patient mor-
tality, readmission, and quality of life were not statistically sig-
nificantly different between treatment arms. In a randomized
efficacy trial conducted at 2 Spanish hospitals [16], 224 patients
with CAP in PSI classes II and III were randomly allocated to
receive outpatient or inpatient care. Outpatients had a statis-
tically significantly higher rate of satisfaction with care, com-
pared with inpatients, with no statistically significant differences
in readmission or mortality rates. In a large, cluster-randomized
effectiveness trial that enrolled 1901 nonhypoxemic patients
with CAP in PSI risk classes I–III from 32 US hospital emer-
gency departments [17], a guideline recommending outpatient
care for low-risk, nonhypoxemic patients was implemented us-
ing low-, moderate-, and high-intensity guideline-implemen-
tation strategies. Patients whose cases were managed using the
moderate- and high-intensity strategies received treatment as
outpatients statistically significantly more frequently than did
patients whose cases were managed using the low-intensity
strategy (37.5% and 61.0% vs. 61.9%, respectively), without
compromising patient safety. Finally, in a prospective, con-
trolled study involving 449 low-risk patients with CAP from
16 French hospital emergency departments [18], 50.9% of non-
hypoxemic patients in PSI risk classes I–III received treatment
as outpatients in emergency departments that used the PSI,
compared with 29.3% of patients in emergency departments
that did not use the PSI. After adjustment for pneumonia se-
verity, mortality was lower in the emergency departments that
used the PSI.
Current methodological standards require that a clinical pre-
diction rule must demonstrate a beneficial effect on patient
care in a formal impact analysis before its use as a decision rule
can be recommended [19]. Overall, these 5 studies that enrolled
a total of 3949 low-risk patients with CAP at 60 study sites in
4 countries (the United States, Canada, France, and Spain)
uniformly demonstrate the positive impact of the PSI on patient
care. With its validation according to strict methodological cri-
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Table 4. Studies comparing the prognostic accuracy of the pneumonia severity index (PSI) and the CURB-65 score.
Study characteristic
Aujesky et al.
[20]
Buising et al.
[21]
Capelastegui et al.
[22]
Man et al.
[23]
Ananda-Rajah et al.
[24]
Sites 32 EDs in the US 1 ED in Australia 1 ED in Spain 1 ED in Hong Kong 1 ED in Sweden
Total no. of patients 3181 Immuno-
competent adults
392 Immuno-
competent adults
1776 Immuno-
competent adults
1016 Immuno-
competent adults
408 Immuno-
competent adults
Patients classified as low risk, %
PSI risk classes I–III 68 44 64 47 28
CURB-65 scores 0–1 61 59 57 43 29
30-Day mortality, %
PSI risk classes I–III 1.4 0.6 0.7 2.9 3.5
CURB-65 scores 0–1 1.7 … 0.4 3.0 6.7
Sensitivity for 30-day mortality, %
PSI risk classes IV–V 79 97 93 84 94
CURB-65 scores 2–5 77 … 97 85 87
Specificity for 30-day mortality, %
PSI risk classes IV–V 70 48 67 50 32
CURB-65 scores 2–5 63 … 60 46 33
PPV for 30-day mortality, %
PSI risk classes IV–V 11 16 18 14 20
CURB-65 scores 2–5 9 … 15 13 19
NPV for 30-day mortality, %
PSI risk classes IV–V 99 99 99 97 97
CURB-65 scores 2–5 98 … 100 97 93
AUC for 30-day mortality
PSI 0.81 0.82 0.89 0.74 0.72
CURB-65 0.76 0.82 0.87 0.73 0.69
NOTE. The CURB-65 prediction rule uses 5 variables (confusion, urea level 17 mmol/L, respiratory rate 30 breaths/min, low systolic or diastolic blood
pressure, and age 65 years). AUC, area under the receiver operating characteristic curve; CAP, community-acquired pneumonia; ED, emergency department;
NPV, negative predictive value; PPV, positive predictive value.
teria, its broad validation, and its positive effect on patient care
shown in various impact analyses, the PSI has achieved the
highest level of methodological rigor (level 5 evidence) for a
clinical prediction rule (table 3) [19]. According to current
methodological standards, level 5 prediction rules may be used
in various settings with confidence that the application will
augment the quality and/or efficiency of patient care [19].
Despite the methodological strengths of the PSI and the em-
pirical evidence supporting its effectiveness in guiding the
choice of the initial site of treatment, those who use the PSI
clinically must be aware of its limitations. First, use of the PSI
as a decision aid has been restricted to immunocompetent
adults with CAP, with exclusion of children, pregnant women,
patients with immunosuppression (e.g., HIV-infected patients),
and those with hospital-acquired pneumonia [7]. Second, to
simplify application of the rule, the PSI was constructed with
dichotomous predictor variables (abnormal vs. normal), which
may oversimplify the manner in which physicians interpret the
results of some of its predictor variables. For example, a phy-
sician would be unlikely to discharge a previously healthy 25-
year-old patient with severe systolic hypotension (e.g., systolic
blood pressure, !60 mm Hg), tachycardia (e.g., pulse, 1150
beats/min), and no additional pertinent prognostic factors, de-
spite assignment to PSI risk class II. Third, patients designated
as low risk (PSI risk classes, I–III) may have important medical
and psychosocial contraindications to outpatient care [7]. For
example, administration of oral antibiotics in an outpatient
setting to patients with intractable vomiting is not an option.
Likewise, patients who are injection drug users, abuse alcohol,
or have severe psychiatric conditions may require hospitali-
zation to ensure compliance with treatment. Patients with se-
verely impaired cognitive function who are unable to perform
activities of daily living independently and those with little
social support may also require inpatient care regardless of the
severity of illness. Finally, the fact that the PSI consists of 20
predictor variables complicates its use in clinical practice. How-
ever, the use of pocket cards, electronic handheld devices, or
Internet support systems greatly facilitates the application of
the PSI in clinical practice.
COMPARISON OF THE PSI WITH THE CURB-65
PREDICTION RULE
Among the various clinical prediction rules for prognosis of
CAP, the CURB-65 score has recently emerged as a potential
alternative to the PSI [8]. On the basis of prediction rules
originally developed to identify patients with severe pneumonia
[2, 10], Lim et al. [8] used data from 1068 patients with CAP
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to derive and internally validate the CURB-65 prediction rule.
The CURB-65 prediction rule assigns less prognostic impor-
tance to comorbid illnesses and uses 5 variables (confusion,
urea level 17 mmol/L, respiratory rate 30 breaths/min, low
systolic or diastolic blood pressure, and age65 years) to assign
a score on a 6-point scale (0–5). Scores of 0–1 are considered
to indicate low risk, with a 30-day mortality rate of 0%–2.1%
[8].
The 5 largest studies that directly compared the performance
of the PSI with that of CURB-65 as disease-specific prediction
rules for prognosis in immunocompetent adults have shown
that the PSI identifies a slightly greater proportion of patients
as at low risk for short-term mortality and has a slightly higher
discriminatory power for mortality than does the CURB-65
score (table 4) [20–24]. In contrast to the PSI, the effectiveness
and safety of using the CURB-65 score to guide clinical practice
have not been assessed in clinical studies. Thus, the advantages
of the PSI over the CURB-65 prediction rule are its broader,
external validation; superiority in identifying low-risk patients;
and proven benefits in guiding patient care in large-scale impact
trials [5–17].
Because of the CURB-65 score’s ease of use, compared with
the PSI, the updated 2004 British Thoracic Society pneumonia
guidelines recommend that patients with a CURB-65 score of
0 or 1 may be suited to outpatient treatment, even in the
absence of a formal impact study of the CURB-65 score as a
decision aid [25]. The 2007 guidelines from the Infectious Dis-
eases Society of America and American Thoracic Society rec-
ommend the use of either the PSI or the CURB-65 score for
screening of patients with CAP who are potential candidates
for outpatient care [26].
CONCLUSION
Over the past decade, the PSI has evolved from a prediction
rule for prognosis to a decision aid to guide the choice of the
initial site of treatment for patients with CAP. This evolution
was facilitated by strict adherence to accepted methodological
standards in its development; broad, external validation across
heterogeneous patient populations; and consistent findings
from large clinical trials demonstrating its effectiveness and
safety in increasing the proportion of low-risk patients who
receive treatment in the outpatient setting. Direct comparisons
of the PSI with other disease-specific prediction rules for prog-
nosis suggest that the PSI identifies a slightly greater proportion
of low-risk patients and has a slightly greater discriminatory
power for predicting mortality. Because of its methodological
rigor, superior prognostic accuracy, and proven effectiveness as
a decision aid, the PSI has become the reference standard for
severity adjustment and risk stratification of patients with CAP.
Acknowledgments
Supplement sponsorship. This article was published as part of a sup-
plement entitled “Workshop on Issues in the Design and Conduct of Clin-
ical Trials of Antibacterial Drugs for the Treatment of Community-Acquired
Pneumonia,” sponsored by the US Food and Drug Administration and the
Infectious Diseases Society of America.
Potential conflicts of interest. D.A. and M.J.F.: no conflicts.
References
1. Gilbert K, Fine MJ. Assessing prognosis and predicting patient out-
comes in community-acquired pneumonia. Semin Respir Infect 1994;9:
140–52.
2. Community-acquired pneumonia in adults in British hospitals in
1982–1983: a survey of aetiology, mortality, prognostic factors and
outcome. The British Thoracic Society and the Public Health Labo-
ratory Service. Q J Med 1987; 62:195–220.
3. Daley J, Jencks S, Draper D, Lenhart G, Thomas N, Walker J. Predicting
hospital-associated mortality for Medicare patients: a method for pa-
tients with stroke, pneumonia, acute myocardial infarction, and con-
gestive heart failure. JAMA 1988; 260:3617–24.
4. Black ER, Mushlin AI, Griner PF, Suchman AL, James RL Jr, Schoch
DR. Predicting the need for hospitalization of ambulatory patients with
pneumonia. J Gen Intern Med 1991; 6:394–400.
5. Fine MJ, Hanusa BH, Lave JR, et al. Comparison of a disease-specific
and a generic severity of illness measure for patients with community-
acquired pneumonia. J Gen Intern Med 1995; 10:359–68.
6. Conte HA, Chen YT, Mehal W, Scinto JD, Quagliarello VJ. A prognostic
rule for elderly patients admitted with community-acquired pneu-
monia. Am J Med 1999; 106:20–8.
7. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-
risk patients with community-acquired pneumonia. N Engl J Med
1997; 336:243–50.
8. Lim WS, van der Eerden MM, Laing R, et al. Defining community
acquired pneumonia severity on presentation to hospital: an inter-
national derivation and validation study. Thorax 2003; 58:377–82.
9. Espana PP, Capelastegui A, Gorordo I, et al. Development and vali-
dation of a clinical prediction rule for severe community-acquired
pneumonia. Am J Respir Crit Care Med 2006; 174:1249–56.
10. Neill AM, Martin IR, Weir R, et al. Community acquired pneumonia:
aetiology and usefulness of severity criteria on admission. Thorax
1996; 51:1010–6.
11. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the
management of adults with community-acquired pneumonia: diag-
nosis, assessment of severity, antimicrobial therapy, and prevention.
Am J Respir Crit Care Med 2001; 163:1730–54.
12. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules:
applications and methodological standards. N Engl J Med 1985; 313:
793–9.
13. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules: a review and
suggested modifications of methodological standards. JAMA 1997; 277:
488–94.
14. Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion
of patients with community-acquired pneumonia treated as outpa-
tients: an interventional trial. Arch Intern Med 1998; 158:1350–6.
15. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan
BG. A controlled trial of a critical pathway for treatment of community-
acquired pneumonia. CAPITAL Study Investigators. JAMA 2000; 283:
749–55.
16. Carratala´ J, Fernandez-Sabe N, Ortega L, et al. Outpatient care com-
pared with hospitalization for community-acquired pneumonia: a ran-
domized trial in low-risk patients. Ann Intern Med 2005; 142:165–72.
17. Yealy DM, Auble TE, Stone RA, et al. Effect of increasing the intensity
of implementing pneumonia guidelines: a randomized, controlled trial.
Ann Intern Med 2005; 143:881–94.
PSI: A Decade Later • CID 2008:47 (Suppl 3) • S139
18. Renaud B, Coma E, Labarere J, et al. Routine use of the pneumonia
severity index for guiding the site-of-treatment decision of patients
with pneumonia in the emergency department: a multicenter, pro-
spective, observational, controlled cohort study. Clin Infect Dis
2007; 44:41–9.
19. Reilly BM, Evans AT. Translating clinical research into clinical practice:
impact of using prediction rules to make decisions. Ann Intern Med
2006; 144:201–9.
20. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three
validated prediction rules for prognosis in community-acquired pneu-
monia. Am J Med 2005; 118:384–92.
21. Buising KL, Thursky KA, Black JF, et al. A prospective comparison of
severity scores for identifying patients with severe community acquired
pneumonia: reconsidering what is meant by severe pneumonia. Thorax
2006; 61:419–24.
22. Capelastegui A, Espana PP, Quintana JM, et al. Validation of a pre-
dictive rule for the management of community-acquired pneumonia.
Eur Respir J 2006; 27:151–7.
23. Man SY, Lee N, Ip M, et al. Prospective comparison of three predictive
rules for assessing severity of community-acquired pneumonia in Hong
Kong. Thorax 2007; 62:348–53.
24. Ananda-Rajah MR, Charles PG, Melvani S, Burrell LL, Johnson PD,
Grayson ML. Comparing the pneumonia severity index with CURB-
65 in patients admitted with community acquired pneumonia. Scand
J Infect Dis 2008; 40:293–300.
25. Macfarlane JT, Boldy D. 2004 Update of BTS pneumonia guidelines:
what’s new? Thorax 2004; 59:364–6.
26. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases
Society of America/American Thoracic Society consensus guidelines on
the management of community-acquired pneumonia in adults. Clin
Infect Dis 2007; 44(Suppl 2):S27–72.
